|Jmol-3D images||Image 1|
|Molar mass||165.189 g/mol|
|Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)|
Norsalsolinol is a chemical compound that is produced naturally in the body through metabolism of dopamine. It has been shown to be a selective dopaminergic neurotoxin, and has been suggested as a possible cause of neurodegenerative conditions such as Parkinson's disease and the brain damage associated with alcoholism, although evidence for a causal relationship is unclear.
- Maruyama W, Takahashi T, Minami M, Takahashi A, Dostert P, Nagatsu T, Naoi M (1993). "Cytotoxicity of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines". Advances in Neurology 60: 224–30.
- Maruyama Y, Suzuki Y, Kazusaka A, Fujita S (May 2001). "Norsalsolinol uptake into secretory vesicles via vesicular monoamine transporter and its secretion by membrane depolarization or purinoceptor stimulation in PC12 cells". The Journal of Veterinary Medical Science / the Japanese Society of Veterinary Science 63 (5): 493–7.
- Maruyama Y, Suzuki Y, Kazusaka A, Fujita S (June 2001). "Uptake of the dopaminergic neurotoxin, norsalsolinol, into PC12 cells via dopamine transporter". Archives of Toxicology 75 (4): 209–13.
- Kobayashi H, Fukuhara K, Tada-Oikawa S, Yada Y, Hiraku Y, Murata M, Oikawa S (January 2009). "The mechanisms of oxidative DNA damage and apoptosis induced by norsalsolinol, an endogenous tetrahydroisoquinoline derivative associated with Parkinson's disease". Journal of Neurochemistry 108 (2): 397–407.
- Dostert P, Strolin Benedetti M, Della Vedova F, Allievi C, La Croix R, Dordain G, Vernay D, Durif F (1993). "Dopamine-derived tetrahydroisoquinolines and Parkinson's disease". Advances in Neurology 60: 218–23.
- Musshoff F, Daldrup T, Bonte W, Leitner A, Lesch OM (October 1997). "Salsolinol and norsalsolinol in human urine samples". Pharmacology, Biochemistry, and Behavior 58 (2): 545–50.
- Musshoff F, Lachenmeier DW, Kroener L, Schmidt P, Dettmeyer R, Madea B (July 2003). "Simultaneous gas chromatographic-mass spectrometric determination of dopamine, norsalsolinol and salsolinol enantiomers in brain samples of a large human collective". Cellular and Molecular Biology (Noisy-le-Grand, France) 49 (5): 837–49.
- Scholz J, Klingemann I, Moser A (April 2004). "Increased systemic levels of norsalsolinol derivatives are induced by levodopa treatment and do not represent biological markers of Parkinson's disease". Journal of Neurology, Neurosurgery, and Psychiatry 75 (4): 634–6.
- Musshoff F, Lachenmeier DW, Schmidt P, Dettmeyer R, Madea B (January 2005). "Systematic regional study of dopamine, norsalsolinol, and (R/S)-salsolinol levels in human brain areas of alcoholics". Alcoholism, Clinical and Experimental Research 29 (1): 46–52.